Ascendis Pharma A/S is a dynamic, patient-focused biopharmaceutical company committed to improving patients' lives by developing innovative, best-in-class therapies. Utilizing its unique TransCon™ (Transient Conjugation) technology platform, Ascendis aims to create new treatments that offer enhanced efficacy, safety, and/or convenience. The company's primary focus areas include endocrinology rare diseases and oncology, with a growing pipeline of product candidates and marketed products. Ascendis Pharma is dedicated to scientific excellence and translating groundbreaking research into meaningful therapeutic solutions for unmet medical needs globally.
Serves as the global corporate headquarters, overseeing worldwide strategy, research and development leadership, finance, legal, and other core administrative functions. It's a key hub for innovation and global operations management.
Modern office and laboratory facilities situated in the redeveloped Tuborg Havn (Tuborg Harbor) area, known for its contemporary architecture and waterfront views. The design likely emphasizes collaborative workspaces and state-of-the-art research infrastructure.
Characterized by a strong emphasis on scientific innovation, patient-centricity, and collaboration. Employees often describe a fast-paced, dynamic environment driven by a shared mission to develop transformative therapies. The culture encourages teamwork, open communication, and a commitment to quality and ethical standards.
The Hellerup headquarters is central to Ascendis Pharma's identity and global strategy, anchoring its presence in the Medicon Valley, one of Europe's leading life science clusters. This location facilitates access to talent, research collaborations, and a supportive biotech ecosystem.
Ascendis Pharma operates globally with key functions distributed across its international sites. Research and development are primarily conducted in Denmark, Germany, and the United States (California). Clinical development, regulatory affairs, and medical affairs are strong in the U.S. (New Jersey and California). Commercial operations are established in the U.S. (California) and are expanding in Europe to support product launches. Corporate functions are centered at its global headquarters in Denmark.
Tuborg Boulevard 5
Hellerup
Denmark
Address: 500 Oracle Parkway, Suite 225, Redwood City, CA 94065, USA
Hub for research and early development, and U.S. commercial operations, leveraging the Bay Area's biotech ecosystem.
Address: 500 Emerson Street, Palo Alto, CA 94301, USA
Serves as a key U.S. hub, focusing on corporate operations, business development, and maintaining a presence in the San Francisco Bay Area biotech ecosystem.
Address: 600 College Road East, Suite 2200, Princeton, NJ 08540, USA
Centralizes U.S. clinical trial management, medical strategy, and interactions with regulatory bodies like the FDA, leveraging the region's pharmaceutical talent pool.
Address: Im Neuenheimer Feld 583, D-69120 Heidelberg, Germany
Significant European R&D hub, focusing on later-stage product development, manufacturing process optimization, and research activities, benefiting from Germany's strong biotech infrastructure.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Ascendis Pharma' leadership includes:
Ascendis Pharma has been backed by several prominent investors over the years, including:
During the past 12 months, Ascendis Pharma announced several key internal promotions within its executive team in January 2024, elevating senior leaders to Executive Vice President roles to further strengthen its capabilities in clinical development, oncology, and human resources. No high-profile executive departures were publicly announced.
Discover the tools Ascendis Pharma uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Ascendis Pharma A/S appears to use a primary email format of [first_name_initial][last_name_initial]@ascendispharma.com for some staff, particularly senior leadership (e.g., jm@ascendispharma.com for Jan Mikkelsen). Other common formats like [first_name].[last_name]@ascendispharma.com or [first_name_initial][last_name]@ascendispharma.com may also be in use across the organization. Verification is recommended for specific contacts.
[fi][li]@ascendispharma.com
Format
es@ascendispharma.com
Example
75%
Success rate
Ascendis Pharma Investor Relations • May 21, 2024
Ascendis Pharma A/S announced the pricing of an upsized underwritten public offering of 4,347,827 American Depositary Shares ('ADSs'), each representing one ordinary share of Ascendis, at a public offering price of $115.00 per ADS....more
Ascendis Pharma Investor Relations • May 8, 2024
Ascendis Pharma A/S reported financial results for the first quarter ended March 31, 2024, highlighting revenue growth from SKYTROFA and YORVIPATH, and progress in its pipeline programs....more
Ascendis Pharma Investor Relations • April 24, 2024
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation for YORVIPATH® (palopegteriparatide), a long-acting parathyroid hormone replacement therapy for adults with chronic hypoparathyroidism....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Ascendis Pharma, are just a search away.